Connect Biopharma Holdings Limited · NASDAQ:CNTB
Connect Biopharma — Investor Presentation (June 2021)
31 slides from Connect Biopharma's investor presentation, Jun 3, 2021
Slide 1: Developing Next-Generation Therapeutics for T Cell Driven Inflammatory Diseases
Exhibit 99.2 DEVELOPING NEXT-GENERATION THERAPEUTICS FOR T CELL DRIVEN INFLAMMATORY DISEASES Corporate Presentation - June 2021 NASDAQ: CNTBExhibit 99.2 DEVELOPING NEXT-GENERATION THERAPEUTICS FOR T CELL DRIVEN INFLAMMATORY DISEASES Corporate Presentation - June 2021 NASDAQ: CNTB
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements • Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-party sources and Connect’s own internal estimates and research. While we believe these third-party sources to be reliable a
Slide 3: Connect is Well-Positioned for Value Creation
3 Connect is Well-Positioned for Value Creation Targeting inflammatory diseases (Dermatology, Gastroenterology, Respiratory) with high unmet need Large Opportunity Ambition to develop molecules with “First-in-class” or “Best-in-class” potential CBP-201:- Interleukin-4-receptor alpha (IL4Ra) blocker
Slide 4: Connect's discovery approach is designed to offer significant speed and mechanistic advantages
Connect’s discovery approach is designed to offer significant 4 speed and mechanistic advantages … T Cell SCREENING LIBRARY Affinity Signaling Modulation Drug Candidate Traditional Method Requires more steps, yields fewer candidates and may miss molecules with potent T cell modulation activity Candi
Slide 5: A pipeline of potentially highly differentiated therapies
5 A pipeline of potentially highly differentiated therapies Connect Biopharma has Global Development & Commercialization Rights to all Product Candidates INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Atopic Dermatitis (AD) CBP-201 Antibody targeting IL-4Rα Asthma cytokine receptor (Th2 cell modulat
Slide 6: Multiple Clinical Trial Catalysts Anticipated In Next 24 Months
Multiple Clinical Trial Catalysts Anticipated In Next 24 Months 6 (Subject to ongoing Covid-19 restrictions) CBP-201 CBP-201 CBP-201 AD Ph2 AD Ph2b AD Ph3 Full Enrollment Topline Launch CBP-201 CBP-201 CBP-201 Asthma Asthma Ph2 Asthma Ph2 Ph2 Launch Full Enrollment Topline CBP-201 CBP-201 CBP-201 CR
Slide 7: Leading Global Investors, Strong Cash Position
7 Leading Global Investors, Strong Cash Position Funded through end of 2022 • $220 million raised pre-IPO ‒ Completed $135 million Series C led by RA Capital in December 2020 • ~$220 million raised at IPO, closed March 2021 (NASDAQ: CNTB) ‒ Underwriters’ option to purchase exercised in full ‒ Jeffer
Slide 8: CBP-201: A next generation anti-IL-4Rα antibody
CBP-201: A next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody in development for type 2 inflammatory diseasesCBP-201: A next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody in development for type 2 inflammatory diseases
Slide 9: CBP-201: A Next Generation IL-4Rα Blocker
9 CBP-201: A Next Generation IL-4Rα Blocker Mechanism of Action - Dual Inhibition of IL-4 and IL-13 – A validated target IL-4/IL-13 Pathway Dual Inhibition is Effective Across Many Th2-mediated diseases • CBP-201 is a novel, human monoclonal IgG4 antibody directed against IL-4Rα, a common subunit fo
Slide 10: CBP-201: Phase 1b – Trial Design & Primary Endpoint
10 CBP-201: Phase 1b – Trial Design & Primary Endpoint AE Profile Consistent with Data Reported in Studies of Existing IL-4Ra Blockers A Randomized, Double-Blind, Placebo-Controlled Multi-Centered, Dose-Escalation Trial of Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects Wi
Slide 11: CBP-201: Phase 1b – Efficacy Results - Rapid Onset of Action
11 CBP-201: Phase 1b – Efficacy Results - Rapid Onset of Action Improvements in Key Physician & Patient Assessed Endpoints * EASI – Mean Change from Baseline IGA 0,1 Responders (%) Weekly Average P-NRS-Frequency Weekly Average P-NRS-Severity (%) (n=8) (n=8) (n=8) ` (n=8) Placebo CBP-201 75mg Placebo
Slide 12: CBP-201: Phase 1b – Efficacy Results EASI-50 and IGA 0,1
12 CBP-201: Phase 1b – Efficacy Results Week 4 EASI-50 and IGA 0,1 (% Responders) in AD patients in Early Phase Clinical Trials For Illustrative Purposes Only:- Not a head-to-head comparison. Differences exist between trial designs and subject characteristics and caution should be exercised when com
Slide 13: CBP-201: Phase 1b – Reported IGA 0,1 Data of Select Biologics
13 CBP-201: Phase 1b – Efficacy Results Reported IGA 0,1 % Responders Data of Select Biologics in Development with AD patients For Illustrative Purposes Only:- Not a head-to-head comparison. Differences exist between trial designs and subject characteristics and caution should be exercised when comp
Slide 14: CBP-201: Global Phase 2b AD Trial Design
TRIAL FULLY 14 CBP-201: Global Phase 2b AD Trial Design ENROLLED Trial designed for dose-ranging, maximal efficacy and possible longer dosing interval (NCT04444752) A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Trial of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of C
Slide 15: CBP-201: Global Phase 2b Asthma Trial Design
TRIAL 15 CBP-201: Global Phase 2b Asthma Trial Design ONGOING Trial designed for dose-ranging (NCT04773678) A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammatio
Slide 16: CBP-201: Global Phase 2b CRSwNP Trial Design
TRIAL 16 CBP-201: Global Phase 2b CRSwNP Trial Design ONGOING Trial designed for dose-ranging, maximal efficacy and possible longer dosing interval (NCT04783389) A multi-center, randomized, double-blind, placebo-controlled study to evaluate the effect of CBP-201 on a background of mometasone furoate
Slide 17: CBP-307: A next generation selective S1P1 modulator
CBP-307: A next generation selective sphingosine 1-phosphate receptor 1 modulator (S1P1) in development for IBDCBP-307: A next generation selective sphingosine 1-phosphate receptor 1 modulator (S1P1) in development for IBD
Slide 18: CBP-307: A Next Generation S1P1 Modulator
18 CBP-307: A Next Generation S1P1 Modulator Mechanism of Action – S1P1 Modulator – A validated target • Blocking T Cell Egress from Lymph Nodes Reduces Inflammation Implicated in Many T cell-mediated 1 diseases • S1P1 mediates T cell movement from lymph nodes into circulation, and hence migration t
Slide 19: CBP-307: Pre-Clinical Highly selective for S1P1
19 CBP-307: Pre-Clinical Highly selective for S1P1, with up to 80,000-fold selectivity for S1P1 vs. S1P3 High selectivity for S1P1 EC (nM) 50 Name S1P1 S1P2 S1P3 S1P4 S1P5 1 1 2 2 2 2 CBP-307 0.09 >10,000 7,900 19 3.97 3 Ozanimod 2.99 >10,000 >10,000 >10,000 29.32 (CC-1122273) Etrasimod 6.10 >10,000
Slide 20: CBP-307: Phase 1 – PK / PD Profile
20 CBP-307: Phase 1 – PK / PD Profile Supports QD Dosing, Rapid Onset of Action, Strong PD effect and Rapid Offset on Drug Discontinuation • Oral, 25-hour half-life supports QD dosing • Rapid 50% ALC reduction by day 7, with steady-state by day 14 • Rapid washout after discontinuation correlates wit
Slide 21: CBP-307: Phase 1 – PK / PD Profile vs. Etrasimod and Ozanimod
21 CBP-307: Phase 1 – PK / PD Profile Oral, QD Dosing, similar onset and offset of action to etrasimod and faster offset vs. ozanimod, in HV For Illustrative Purposes Only:- Not a head-to-head comparison. Differences exist between trial designs and subject characteristics and caution should be exerc
Slide 22: CBP-307: Phase 1 – Safety Results
22 CBP-307: Phase 1 – Safety Results – Generally Well-Tolerated No Unexpected Adverse Events • Once daily doses of up to 0.3 mg of CBP-307 were generally well-tolerated. • Most frequent AEs across all dose regimens included ‒ Low white blood cells ‒ Headache • Most AEs were mild or moderate • No cli
Slide 23: CBP-307: Global Phase 2 Trial in Moderate-to-Severe UC
TRIAL 23 CBP-307: Global Phase 2 Trial in Moderate-to-Severe UC ONGOING CBP-307CN002 - Trial Design – 52-Week Study (Induction / Maintenance / Follow-Up) (NCT04700449) A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of CBP-307 in Patients With Moderate to Sev
Slide 24: CBP-307: Global Phase 2 Trial in Moderate-to-Severe UC
TRIAL 24 CBP-307: Global Phase 2 Trial in Moderate-to-Severe UC ONGOING CBP-307CN002 - Trial Design – 52-Week Study (Induction / Maintenance / Follow-Up) (NCT04700449) A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of CBP-307 in Patients With Moderate to Sev
Slide 25: CBP-307: Phase 2 Trial in Moderate-to-Severe CD (Ended)
25 CBP-307: Phase 2 Trial in Moderate-to-Severe CD (Ended) CBP-307CN003 – Results - Generally well-tolerated with clear evidence of clinical response % of patients with any reduction in the specified endpoint at week 12 vs. • Due to the COVID-19 pandemic, this trial was ended early baseline with onl
Slide 26: CBP-174: Peripherally-restricted H3R antagonist
CBP-174: A novel, peripherally-restricted, Histamine Receptor-3 (H3R) antagonist in development for pruritus associated with inflammatory skin diseaseCBP-174: A novel, peripherally-restricted, Histamine Receptor-3 (H3R) antagonist in development for pruritus associated with inflammatory skin disease
Slide 27: Chronic Pruritis Associated with Atopic Dermatitis (AD)
27 Chronic Pruritis Associated with Atopic Dermatitis (AD) Remains underserved with no approved treatments for chronic pruritus associated with inflammation Chronic pruritus associated with AD can significantly impact quality of life with patients often suffering from generalized anxiety, depression
Slide 28: CBP-174: A peripherally-restricted, H3R antagonist
28 CBP-174: A peripherally-restricted, H3R antagonist Mechanism of Action – Antagonism of H3R, predominantly at peripheral sites Pruritus in AD is mediated by a variety of pruritogens • CBP-174 is a novel small molecular entity that is a potent antagonist of the histamine 3 receptor (H3R) • Highly s
Slide 29: CBP-174: Preclinical Results – POC in Animal Model
29 CBP-174: Preclinical Results – POC in Animal Model Rapidly reduces scratching bouts in a mouse model of pruritus 200 *P<0.01 vs vehicle 150 * * • CBP-174 had a strong anti-itch effect * in mice with a rapid onset of action, within the first 30 minutes of dosing 100 50 0 Vehicle 0.03 0.1 0.3 1 CBP
Slide 30: CBP-174: Phase 1a – Trial Design
TRIAL 30 CBP-174: Phase 1a – Trial Design ONGOING First-in-human, single-center, double-blind, randomized, SAD in healthy volunteers (NCT04811469) A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic
Slide 31: NASDAQ: CNTB
NASDAQ: CNTBNASDAQ: CNTB
Connect Biopharma Holdings — Investor Presentation (June 2021) on 6ix